Mitroflow DL Post Approval Study- North America

A trial with no phase registered on ClinicalTrials.gov. The registry status is terminated. It enrolled 186 participants.

Also called NCT02351726

  • Study
  • In this atlas

Overview

Design
Interventional study; allocation not applicable; no masking; primary purpose treatment
Phase
Not applicable
Enrolled
  • 186 participants (enrolled count) (from the registry)
Sponsor
  • LivaNova Registry lists this organization as the lead sponsor
Registry
  • NCT NCT02351726
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
United States (from the registry)
Registry status
  • Terminated (from the registry)

Technical summary

Registry record NCT02351726. Allocation not applicable; no masking; primary purpose treatment. Start 2015-03 (actual); primary completion 2019-12-31 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Mitroflow DL Post Approval Study- North America
Condition
Aortic Stenosis
Condition
Aortic Regurgitation
Condition
Aortic Valve Insufficiency
Condition
Heart Valve Diseases
Condition
Cardiovascular Abnormalities
Condition
Cardiovascular Diseases
Condition
Congenital Abnormalities
Condition
Heart Diseases
Condition
Pathological Conditions, Anatomical
Intervention (Device)
Mitroflow DL
Lead sponsor
LivaNova (class: industry)

Record details

Record id
cardio:ct-nct02351726
Content hash
60dbbce3a36b0f58714652761d95f6c49e44d0acccd9100990dd1d0d8ce9bc16